全球immuno-oncology market根据Polaris市场研究的一项新的研究，预计尺寸预计将达到2025美元的388.9亿美元。betway苹果下载那个报告“免疫肿瘤学（I-O）市场规模，趋势，通过治疗方法分析（单克隆抗体，治疗疫苗，检查点抑制剂和细胞因子）;通过新的靶标（IDO1I，LAG-3 CPI，葡萄酒病毒，刺激激动剂，TLR激动剂，HDACI，TIL，VEGFI，Meki，TIGIT，CPI，GITR激动剂，TGF-B陷阱和A2AR拮抗剂/ CD73i）;通过肿瘤类型;按地区：市场规模和预测，2020 - 2026“详细了解当前市场动态，并提供未来市场增长分析。
Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body’s natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.
免疫肿瘤学代表了一种创新的癌症研究方法，寻求利用身体自身的免疫系统来对抗肿瘤细胞的癌症研究。目前，世界处于该科学的最前沿，并在各种癌症中调查了几种开发化合物，以及继续研究新用途的经批准的免疫肿瘤医学。对选定疗法的患者更精确的靶向是肿瘤学中的另一个重要领域。临床生物标志物和药物替代研究越来越多地用于鉴定最容易受益于调查药剂的患者的群体和亚组，以最大限度地提高其潜在效益。
全球immuno-oncology market is driven by the factors such as rising occurrence of different forms of cancer, technological advancements in the field of immune oncology for cancer treatment, and rising awareness concerning the benefits of ablation procedures over conventional treatment procedures. Moreover, rising number of ablation centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally. Additionally, the developments in oncology treatments, leading to the increased development of pioneering products are also advancing towards significant growth of the global Immune Oncology market.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below://m.jiayuancx.com/Industry-analysisal/immuno-oncology-io-market/Request-for-sample.
新型药剂的研究中也观察到越来越多的趋势，以及组合中临床试验数量的增加以及单药治疗。免疫肿仓学中最值得注意的新药是IDO的，LAG-3，TIGIT，TIM-3，Vista，KIR，NKG2A，B7-H3 / H4。该报告还强调的是氯霉菌病毒，新抗原疗法，TCR疗法和汽车-T疗法。
处理类型的基础上,全球免疫-oncology market is segmented into Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines. Checkpoint inhibitors were the largest treatment process segment in 2019 that accounted for 55.2% of the overall revenue. On the basis of novel targets, the global market is segmented into IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i. VEGFi was the largest novel target segment that was used for immuno-oncology treatment processes in 2019 with a total market share of 11.2%. on the basis of cancer type, the global immuno-oncology Market is segmented into Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Head, face & Neck Cancer, Bladder Cancer, Classical Hodgkin’s Lymphoma, Merkel Cell, and carcinoma. Revenue share of immuno-oncology treatment for classical hodgkin’s lymphoma was the largest in 2019 i.e. 15.31% among the listed tumor types in the report.
On the basis of geography, North America was the largest regional market in 2019. High levels of spending on cancer treatments, also U.S. being one of the major country y with a huge population of cancer affected people on a global scale, the country being the host to the development of this technology, higher frequency of innovations of immuno oncology treatments or processes in the region specially in the U.S. etc., all of these factors have driven significant investment and alongside the demand for IO in the region. These factors have driven the North American market since the inception of this technology and over the forecast period it is expected to increase further.
在全球免疫肿瘤学市场中运营的一些关键球员是布里斯托尔迈尔斯Squibb，Merck，Astrazeneca，Roche举行AG，Pfizer Inc.和Infyte公司等。
Polaris Market research has segmented the Immuno-oncology market report on the basis of Treatment Approaches, novel targets, tumor types, and by region
免疫肿瘤学治疗方法前景（收入，百万，2015 - 2025）
- 单克隆抗体
- 治疗疫苗
- Checkpoint Inhibitors
- 细胞因子
免疫肿瘤学小说目标前景（收入，百万，2015 - 2025）
- IDO1i.
- LAG-3 CPI
- 溶瘤病毒
- 刺痛者
- TLR激动师
- HDACi
- 直到
- VEGFi
- 梅基
- TIGIT
- CPI
- GITR agonist
- TGF-B陷阱
- A2AR拮抗剂/ CD73i
Immuno-Oncology Tumor Type Outlook (Revenue, USD Million, 2015 – 2025)
- Melanoma
- Non-Small Cell Lung Cancer
- 肾细胞癌
- Head & Neck Cancer
- 膀胱癌
- 古典霍奇金的淋巴瘤
- Merkel细胞癌
- Others
Immuno-Oncology Regional Outlook (Revenue, USD Million, 2015 – 2025)
- North America
- U.S.
- 加拿大
- Europe
- 德国
- UK
- Asia Pacific
- China
- 印度
- 日本
- Latin America
- Mexico
- Middle East & Africa